BlueCross BlueShield
Federal Employee Program
Federal Employee Program®
1310 G Street, N.W.
Washington, D.C. 20005
202.942.1000
Fax 202.942.1125

Xgeva

Description

Xgeva (denosumab)

Background
Xgeva is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors and for treatment of giant cell tumor of bone. Xgeva binds to the protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Increased osteoclast activity is a mediator of solid tumor bone metastases. Similarly, giant cell tumors of bone and osteoclast-like giant cells contribute to osteolysis and [bone] tumor growth. Xgeva prevents activation of osteoclasts, their precursors, and osteoclast-like giant cells (1).

Regulatory Status
FDA-approved indications: Xgeva is a RANK ligand (RANKL) inhibitor indicated for: (1)

- Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
- Hypercalcemia of malignancy refractory to bisphosphonate therapy

Xgeva is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with Xgeva (1).

Xgeva may increase risks for osteonecrosis of the jaw, hypocalcemia, and atypical femoral fracture (1).

Related policies

Evenity, Parathyroid Hormone Analogs, Prolia

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Xgeva may be considered **medically necessary** if the conditions indicated below are met.

Xgeva may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 13 years of age or older

Diagnosis

Patient must have the following:

1. Giant cell tumor of bone
    a. Tumor is unresectable or surgical resection is not recommended
    b. Pre-existing hypocalcemia must be corrected prior to initiating therapy
    c. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Bone metastases from solid tumors
2. Multiple myeloma

AND ALL of the following for **BOTH** indications above:

a. At high risk for skeletal-related events

b. Pre-existing hypocalcemia must be corrected prior to initiating therapy
c. Inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
    i. IV Bisphosphonate
    ii. Pamidronate
    iii. Zoledronic acid

3. Hypercalcemia of malignancy
    a. Disease must have relapsed or progressed after bisphosphonate therapy

AND the following for **ALL** indications:

a. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)

Prior – Approval *Renewal* Requirements

Age 13 years of age or older

Diagnosis

Patient must have the following:

1. Giant cell tumor of bone
    a. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Bone metastases from solid tumors
2. Multiple myeloma
3. Hypercalcemia of malignancy

AND the following for **ALL** indications:

a. **NO** concurrent use with another RANKL-inhibitor (see Appendix 1)

Policy Guidelines

Pre - PA Allowance

None

Prior – Approval Limits

Quantity 5 vials per 84 days

Duration 3 months

Prior – Approval *Renewal* Limits

Quantity 3 vials per 84 days

Duration 12 months

Rationale

Summary

Xgeva an osteoclast inhibitor is used to treat complications of bone metastases in patients with multiple myeloma and in patients with solid tumor cancers, for treatment of giant cell tumor of bone and for hypercalcemia of malignancy refractory to bisphosphonate therapy. Xgeva may increase risks for osteonecrosis of the jaw, hypocalcemia, and atypical femoral fracture. The safety and efficacy of Xgeva have not been established in pediatric patients except in skeletally mature adolescents with giant cell tumor of bone (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Xgeva while maintaining optimal therapeutic outcomes.

References

1. Xgeva [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2020.

Policy History

Date	Action
March 2015	Addition to PA Annual editorial review and reference update Added new indication hypercalcemia of malignancy

June 2015	Annual editorial review and reference update
December 2015	Annual editorial review and reference update Addition to the bone metastases of inadequate treatment response, intolerance, or contraindication to one of the following: IV bisphosphonate, pamidronate, or zoledronic acid and addition of quantity limits and change to initial PA duration to 3 months per PMPC
March 2016	Annual review Policy number changed from 5.07.18 to 5.30.18
September 2016	Annual review
December 2017	Annual editorial review and reference update Addition of age requirement to renewal section
January 2018	Addition of multiple myeloma indication Removal of the requirement of no concurrent diagnosis of multiple myeloma
March 2018	Annual review
September 2019	Annual review and reference update
December 2020	Annual review and reference update
December 2021	Annual review
December 2022	Annual review. Changed policy number to 5.30.018
December 2023	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 8, 2023 and is effective on January 1, 2024.

Appendix 1 - List of RANKL Inhibitors

Generic Name	Brand Name
denosumab	Prolia
denosumab	Xgeva